Every material Form 8-K Elanco filed with the SEC in 2024, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Elanco Animal Health appointed Dr. Stacey Ma, currently Executive Vice President of Pharmaceutical Development and Manufacturing at Gilead Sciences, to its Board of Directors effective immediately. The filing says the board was expanded from 14 to 15 members to accommodate the appointment. The change is governance-related and the filing reports no financial results or guidance.
Board appointment effective immediately; Dr. Ma named to Class III with a term expiring in 2027
Board size increased from 14 to 15 members
Dr. Ma also appointed to the Innovation, Science and Technology Committee
Announced in a press release dated November 12, 2024; board appointment made November 11, 2024
Elanco reported third-quarter 2024 revenue of $1,030 million, down 4% on a reported basis and up 1% organic constant currency, and adjusted EPS of $0.13 versus $0.18 a year earlier. Reported net income of $364 million was driven by a $640 million pre-tax gain on the July 2024 sale of its aqua business, but the company's adjusted results declined. It also narrowed its full-year 2024 guidance, lowering the top end of its adjusted EBITDA range and reported EPS range.
Q3 adjusted EBITDA was $163 million, down 24%, and adjusted EBITDA margin was 15.8% versus 20.0% a year earlier.
Full-year 2024 revenue guidance was narrowed to $4,420 million to $4,450 million from $4,410 million to $4,460 million.
Full-year adjusted EBITDA guidance was lowered to $900 million to $930 million from $900 million to $940 million; reported EPS guidance was cut to $0.58 to $0.64 from $0.63 to $0.71.
Fourth-quarter 2024 revenue is expected between $1.00 billion and $1.03 billion, and the company expects to provide detailed 2025 guidance in February 2025.
Elanco Animal Health entered an incremental assumption agreement under its existing senior secured credit facility, adding a new $350 million term loan. Proceeds will repay outstanding obligations under an existing term loan and fund general corporate purposes. The filing says the new facility's interest rate and repayment terms are generally consistent with the existing term loan.
New incremental term facility totals $350,000,000 under the Credit Agreement dated August 1, 2020
Proceeds will repay outstanding obligations under an existing term loan and for general corporate purposes
Facility matures on August 13, 2031; terms generally consistent with the existing term loan
Lenders include Farm Credit Mid-America, PCA as incremental term lender and Goldman Sachs Bank USA as term facility agent
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Elanco filing is on SEC EDGAR ↗. 8-K briefs of other companies →